How Oseltamivir Works And Its Resistance To The Drug
Oseltamivir or Generic Tamiflu is in the class of drugs known as neuraminidase inhibitor, which are antiviral medications. They act to impede or inhibit the mechanics of the viral neuraminidase protein, which in turn stops the virus laden cells from reproducing throughout the body. Sialic acid is located on the membrane surface proteins of regular and potentially host cells. Left unchecked the virus is aided in its mobility through the respiratory system mucus and eventual duplication of the contagion when it is at its most infectious and transmittable state. These neuraminidase inhibitors are effective antivirals against both the influenza A and influenza B viruses, unlike their predecessors.
When antivirals gain extensive use a resistance is built up against them, as was the case with some previous antivirals prior to oseltamivir. The same was expected of tamiflu but in a less recurrent manner than antivirals such as amantadine or rimantadine. Resistance statistics for tamiflu up until July, 2004 based on clinical studies was 0.33% in adults and 4.0% in kids, 1.26% on whole. Mutations, which aid resistance, are lone amino acid residue substitutions in the neuraminidase enzyme.
Information published recently has strongly recommended that antivirals stocks of tamiflu [oseltamivir] be supplemented with more antivirals such as zanamivir [aka Relenza] because of studies done on this type of medication and results of the seasonal influenza and its mutated resistance to tamiflu stocks. This warning is based on the theory that the new 2009 H1N1 swine flu virus could suffer the same resistance pattern.
Research showed that the influenza A virus mutated and resistance to tamiflu was evident. The stats showed a group of fifty children treated oseltamivir and eighteen percent proved resistant to the drug. Another test showed similar numbers when a group of Japanese child counterparts infected with H1N1 influenza found 16.3 percent resistant. The rationale by researchers was simply twofold. Children tend to suffer their infections for longer spans thus leaving more time for virus mutation leading to resistance and that current detection capabilities have become more thorough than in prior studies. Elevated resistance levels were discovered in a young girl in South east Asia undergoing oseltamivir treatment for Avian influenza H5N1 virus.
Further, multiple findings of resistance in these areas of patients with H5N1 flu virus also showed resistance developing. Medical professionals again rationalized that this could be a result of patient’s declining medical conditions. They also speculated that dosage amounts prescribed of oseltamivir for influenza sometimes are not potent enough to thwart the reproduction of the virus thus enabling the replication process and mutated strains. Medical experts agree that personal stockpiling of antivirals such as tamiflu may inevitably pave the way to lower dosages and the unintended appearance of resistant varieties of H5N1 Avian influenza.
Of course the larger concern is an influenza pandemic developing and in the case of H5N1 may seem more likely due to the length of time newer infectious viruses such as the avian seem to last. The result of this longer active period for newer strains is that resistance should be anticipated in the event of a pandemic.
It should be noted that mutated viruses, which develop resistance to antivirals such as oseltamivir, tend to lose strength or become impaired due to the stress placed on the enzyme during mutation at the genetic level making it less efficient. The advantage to antivirals such as oseltamivir and as well as zanamivir is that they are broad spectrum medications and they each target the enzyme of various flu strains. In addition, the growth of a vibrant and resistant flu type does not seem at all inevitable. Also important to note that the resistance found in the child studies for oseltamivir showed that the resistance appeared individually in the kids and was not passed via human contact or with avian contact.
2007 had Japanese health experts discovering neuraminidase-resistant Influenza B illness varieties in people that were not treated with these antiviral medications, stats showed an incidence occur rate of 1.7 percent. In 2008 the WHO [World Health Organization] declared that the early outcome from testing of Canadian influenza A virus, subtype H1N1 illustrated that eight out of eighty one samples proved to be resistant to oseltamivir. There have been resistant varieties appearing in the European Union that are still susceptible to zanamivir.
The Center for Disease Control [or CDC] states that tamiflu may prove unable to combat influenza type A, the most prevalent variety around in 2008. Warnings are being distributed to health care providers to be on the lookout for this strain so they can make every effort to fight the virus by other means if tamiflu fails.